Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $17.00 price target on NeuroPace Inc (NASDAQ: NPCE).

The analyst commented, “On 5/13, NeuroPace (NPCE, OW) reported 1Q25 operating results and increased FY25 revenue guidance. Specifically, NPCE reported total revenue of $22.5 million (Cantor $22.0 million / FactSet consensus $21.8 million), representing YoY growth of ~24%, driven by increased sales of the RNS System as Project Care has demonstrated a contribution to growth, according to the company. Looking ahead, NPCE increased 2025 revenue guidance in the range of ~$93-97 million (Cantor $92.7 million / FactSet consensus $93.7 million) from $92-96 million previously, now representing YoY growth of ~16-21% YoY that we view as conservative, as 1Q results did not reflect the benefit of data from the Post Approval Study published in April.”

For an analyst ratings summary and ratings history on NeuroPace Inc click here. For more ratings news on NeuroPace Inc click here.

Shares of NeuroPace Inc closed at $17.49 yesterday.

You May Also Be Interested In

• Bullish (BLSH) PT Lowered to $30 at Rosenblatt
• Applied Materials (AMAT) PT Lowered to $650 at BofA Securities, 'our top semicap pick is LRCX'
• WeRide Inc (WRD) PT Lowered to $10.70 at BofA Securities